Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.
Profitability
This table compares Lyell Immunopharma and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyell Immunopharma | -1,701,066.75% | -107.62% | -80.01% |
| Pluri | -2,344.59% | N/A | -82.71% |
Earnings and Valuation
This table compares Lyell Immunopharma and Pluri”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyell Immunopharma | $40,000.00 | 9,614.69 | -$274.45 million | ($12.56) | -1.25 |
| Pluri | $1.02 million | 13.54 | -$23.82 million | ($2.45) | -0.45 |
Pluri has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
66.0% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations for Lyell Immunopharma and Pluri, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
Lyell Immunopharma presently has a consensus price target of $40.86, indicating a potential upside of 161.23%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, research analysts plainly believe Lyell Immunopharma is more favorable than Pluri.
Volatility & Risk
Lyell Immunopharma has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Summary
Pluri beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.
About Pluri
Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
